Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

This study was designed to evaluate if subjects who achieve complete remission after 8 weeks
of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term
outcomes and remain in remission longer compared with subjects who demonstrate only partial
remission after acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD. Therefore,
subjects who achieve either complete or partial remission will enter into a 12-month
maintenance phase, during which they will receive MMX mesalamine/mesalazine 2.4g/day given
QD. Remission status for the 2 groups will be evaluated and compared at the end of this
12-month maintenance period. The data obtained from this study will provide scientifically
meaningful information to demonstrate that achieving complete remission (clinical and
endoscopic remission) is important for a better long-term prognosis, or that the current
paradigm of symptomatic treatment is appropriate.